Cargando…

A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi

BACKGROUND: Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Jean Henrique da Silva, Ueda-Nakamura, Tânia, Corrêa, Arlene Gonçalves, Sangi, Diego Pereira, Nakamura, Celso Vataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894994/
https://www.ncbi.nlm.nih.gov/pubmed/24465654
http://dx.doi.org/10.1371/journal.pone.0085706
_version_ 1782299919104606208
author Rodrigues, Jean Henrique da Silva
Ueda-Nakamura, Tânia
Corrêa, Arlene Gonçalves
Sangi, Diego Pereira
Nakamura, Celso Vataru
author_facet Rodrigues, Jean Henrique da Silva
Ueda-Nakamura, Tânia
Corrêa, Arlene Gonçalves
Sangi, Diego Pereira
Nakamura, Celso Vataru
author_sort Rodrigues, Jean Henrique da Silva
collection PubMed
description BACKGROUND: Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole, which unfortunately induces several side effects and it is not successful in the cure of most of the chronic patients. In order to improve the drug armamentarium against Chagas’ disease, in the present study we describe the synthesis of the compound 3-chloro-7-methoxy-2-(methylsulfonyl) quinoxaline (quinoxaline 4) and its activity, alone or in combination with benznidazole, against Trypanosoma cruzi in vitro. METHODOLOGY/PRINCIPAL FINDINGS: Quinoxaline 4 was found to be strongly active against Trypanosoma cruzi Y strain and more effective against the proliferative forms. The cytotoxicity against LLCMK(2) cells provided selective indices above one for all of the parasite forms. The drug induced very low hemolysis, but its anti-protozoan activity was partially inhibited when mouse blood was added in the experiment against trypomastigotes, an effect that was specifically related to blood cells. A synergistic effect between quinoxaline 4 and benznidazole was observed against epimastigotes and trypomastigotes, accompanied by an antagonistic interaction against LLCMK(2) cells. Quinoxaline 4 induced several ultrastructural alterations, including formations of vesicular bodies, profiles of reticulum endoplasmic surrounding organelles and disorganization of Golgi complex. These alterations were also companied by cell volume reduction and maintenance of cell membrane integrity of treated-parasites. CONCLUSION/SIGNIFICANCE: Our results demonstrated that quinoxaline 4, alone or in combination with benznidazole, has promising effects against all the main forms of T. cruzi. The compound at low concentrations induced several ultrastructural alterations and led the parasite to an autophagic-like cell death. Taken together these results may support the further development of a combination therapy as an alternative more effective in Chagas’ disease treatment.
format Online
Article
Text
id pubmed-3894994
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38949942014-01-24 A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi Rodrigues, Jean Henrique da Silva Ueda-Nakamura, Tânia Corrêa, Arlene Gonçalves Sangi, Diego Pereira Nakamura, Celso Vataru PLoS One Research Article BACKGROUND: Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole, which unfortunately induces several side effects and it is not successful in the cure of most of the chronic patients. In order to improve the drug armamentarium against Chagas’ disease, in the present study we describe the synthesis of the compound 3-chloro-7-methoxy-2-(methylsulfonyl) quinoxaline (quinoxaline 4) and its activity, alone or in combination with benznidazole, against Trypanosoma cruzi in vitro. METHODOLOGY/PRINCIPAL FINDINGS: Quinoxaline 4 was found to be strongly active against Trypanosoma cruzi Y strain and more effective against the proliferative forms. The cytotoxicity against LLCMK(2) cells provided selective indices above one for all of the parasite forms. The drug induced very low hemolysis, but its anti-protozoan activity was partially inhibited when mouse blood was added in the experiment against trypomastigotes, an effect that was specifically related to blood cells. A synergistic effect between quinoxaline 4 and benznidazole was observed against epimastigotes and trypomastigotes, accompanied by an antagonistic interaction against LLCMK(2) cells. Quinoxaline 4 induced several ultrastructural alterations, including formations of vesicular bodies, profiles of reticulum endoplasmic surrounding organelles and disorganization of Golgi complex. These alterations were also companied by cell volume reduction and maintenance of cell membrane integrity of treated-parasites. CONCLUSION/SIGNIFICANCE: Our results demonstrated that quinoxaline 4, alone or in combination with benznidazole, has promising effects against all the main forms of T. cruzi. The compound at low concentrations induced several ultrastructural alterations and led the parasite to an autophagic-like cell death. Taken together these results may support the further development of a combination therapy as an alternative more effective in Chagas’ disease treatment. Public Library of Science 2014-01-17 /pmc/articles/PMC3894994/ /pubmed/24465654 http://dx.doi.org/10.1371/journal.pone.0085706 Text en © 2014 Rodrigues et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rodrigues, Jean Henrique da Silva
Ueda-Nakamura, Tânia
Corrêa, Arlene Gonçalves
Sangi, Diego Pereira
Nakamura, Celso Vataru
A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
title A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
title_full A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
title_fullStr A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
title_full_unstemmed A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
title_short A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
title_sort quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against trypanosoma cruzi
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894994/
https://www.ncbi.nlm.nih.gov/pubmed/24465654
http://dx.doi.org/10.1371/journal.pone.0085706
work_keys_str_mv AT rodriguesjeanhenriquedasilva aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT uedanakamuratania aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT correaarlenegoncalves aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT sangidiegopereira aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT nakamuracelsovataru aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT rodriguesjeanhenriquedasilva quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT uedanakamuratania quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT correaarlenegoncalves quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT sangidiegopereira quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi
AT nakamuracelsovataru quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi